List of Excipients in Branded Drug THIOLA EC

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mission Pharmacal Company	THIOLA EC	tiopronin	0178-0901	HYDROXYPROPYL CELLULOSE
Mission Pharmacal Company	THIOLA EC	tiopronin	0178-0901	HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
Mission Pharmacal Company	THIOLA EC	tiopronin	0178-0901	HYPROMELLOSE
Mission Pharmacal Company	THIOLA EC	tiopronin	0178-0901	LACTOSE MONOHYDRATE
Mission Pharmacal Company	THIOLA EC	tiopronin	0178-0901	MAGNESIUM STEARATE
Mission Pharmacal Company	THIOLA EC	tiopronin	0178-0901	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER
Mission Pharmacal Company	THIOLA EC	tiopronin	0178-0901	TALC

THIOLA EC Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: September 25, 2026

THIOLA EC is a delayed-release oral formulation of tiopronin for cystinuria. Its commercial differentiation depends on enteric protection, dose flexibility, tablet manufacturability, and pediatric administration rather than on a new active ingredient. The strongest excipient opportunities are in enteric-coating systems, low-dose pediatric presentations, taste and odor control, film-coating robustness, and supply-chain substitution for critical functional excipients.

THIOLA EC is marketed by Mission Pharmacal under FDA NDA 209817. The product is available as 100 mg and 300 mg delayed-release tablets and is indicated to reduce urinary cystine levels in adults and pediatric patients weighing at least 20 kg who cannot tolerate sufficient fluid intake, alkali therapy, and dietary modification alone.[1]

What is THIOLA EC and how does its formulation work?

THIOLA EC contains tiopronin, a sulfhydryl-containing drug that forms a soluble complex with cystine in the urinary tract. The active ingredient is not new. The formulation opportunity is the delayed-release delivery system.

Attribute	THIOLA EC
Active ingredient	Tiopronin
Dosage form	Delayed-release tablet
Strengths	100 mg and 300 mg
Route	Oral
FDA application	NDA 209817
Sponsor	Mission Pharmacal Company
Primary indication	Cystinuria
Pediatric use	Patients weighing at least 20 kg
Administration	Tablets may be swallowed whole or split along the score line; tablets should not be chewed or crushed
Regulatory category	Small-molecule drug
Biosimilar pathway	Not applicable

The delayed-release design is intended to protect the drug product from release in the stomach and deliver tiopronin after gastric transit. That performance depends on the interaction of the tablet core, seal coat, enteric polymer, plasticizer, anti-tacking agent, coating weight, and dissolution controls.

What excipients are used in THIOLA EC?

The FDA-approved labeling identifies the inactive ingredients used in THIOLA EC. The listed excipients include lactose monohydrate, microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, and tablet-coating materials.[1]

The commercial formulation should be analyzed as a functional system rather than as a simple ingredient list.

Formulation function	Likely excipient role
Dilution and tablet mass	Lactose monohydrate, microcrystalline cellulose
Dry binding	Povidone
Disintegration	Crospovidone
Flow improvement	Colloidal silicon dioxide
Lubrication	Magnesium stearate
Wetting or processing aid	Sodium lauryl sulfate
Delayed release	Enteric polymer coating system
Film flexibility	Plasticizer
Anti-tacking and coating control	Talc or equivalent mineral excipient
Appearance and protection	Film-coating pigments or opacifiers

The precise commercial composition, coating weight, polymer grade, manufacturing sequence, and process parameters are not fully disclosed in the public prescribing information. Those features can create practical barriers even where an ANDA applicant uses the same listed inactive ingredients.

What excipient opportunities exist for THIOLA EC?

1. Enteric polymer substitution

The main opportunity is a functionally equivalent enteric-coating platform. Candidate systems include methacrylic acid copolymers, cellulose acetate phthalate, hypromellose phthalate, hypromellose acetate succinate, and polyvinyl acetate phthalate.

A substitute must match more than the apparent dissolution profile. Development work must address:

• Acid-stage resistance
• Buffer-stage release
• Coating adhesion
• Plasticizer compatibility
• Tablet-to-tablet coating uniformity
• Moisture uptake
• Storage stability
• Mechanical resistance during packaging and transport

For a delayed-release product, an excipient supplier that can provide a validated polymer grade, coating dispersion, and process window has greater commercial value than a supplier selling an undifferentiated polymer.

2. Pediatric dose flexibility

Cystinuria is a chronic disease with pediatric treatment needs. THIOLA EC labeling permits dosing based on body weight and allows dose adjustments.[1] A 100 mg tablet is more suitable for titration than a 300 mg tablet, but both strengths may be difficult for smaller children.

Commercial opportunities include:

• Lower-strength tablets
• Multiparticulate delayed-release systems
• Enteric-coated pellets or granules
• Sprinkle formulations
• Taste-masked oral granules
• Flexible-dose sachets
• Extemporaneous-compounding platforms with controlled release

The principal technical issue is preserving delayed release after tablet splitting or conversion into a pediatric administration format. A product that loses enteric protection after crushing, dispersing, or mixing with food may not be therapeutically interchangeable with THIOLA EC.

3. Taste, odor, and sulfhydryl control

Tiopronin contains a thiol group. Sulfur-containing drugs can create odor and palatability problems, especially in pediatric products. Excipient suppliers can pursue:

• Odor-adsorbing carriers
• Polymer-based taste-masking layers
• Lipid or wax barriers
• Ion-exchange resins
• Microencapsulation
• Flavor systems compatible with enteric protection

The formulation must avoid compromising tiopronin release or creating a new impurity profile. Odor-control technology could support a differentiated 505(b)(2) product if it changes administration or improves pediatric adherence.

4. Moisture and stability control

Enteric polymers and hydrophilic tablet excipients can create moisture-management challenges. Potential solutions include:

• Low-moisture excipient grades
• High-barrier blister packaging
• Desiccant systems
• Moisture-resistant film coats
• Co-processed filler-binder systems
• Reduced hygroscopicity tablet cores

The commercial opportunity is strongest where an excipient change improves shelf life, reduces coating defects, or permits lower-cost packaging without changing the drug substance.

5. Direct-compression platforms

A direct-compression core could reduce manufacturing steps compared with wet granulation. Microcrystalline cellulose, spray-dried lactose, silicified microcrystalline cellulose, and co-processed excipients may improve:

• Flow
• Compressibility
• Weight uniformity
• Tablet hardness
• Production speed
• Scale-up consistency

The technical constraint is the combination of a relatively high drug load, delayed-release coating, tablet splitting, and acceptable dissolution. Excessive hardness can delay disintegration after the enteric layer dissolves. Excessive friability can damage the coating.

What patents protect THIOLA EC?

THIOLA EC is protected by formulation and regulatory exclusivity rather than by a new-compound patent on tiopronin. The relevant intellectual-property categories are:

1. Delayed-release tiopronin compositions.
2. Tablet and coating architecture.
3. Manufacturing processes.
4. Dose forms and administration methods.
5. FDA Orange Book-listed patents.
6. Exclusivity associated with the approved NDA.

Mission Pharmacal has publicly relied on patent protection for the delayed-release product. The current FDA Orange Book entry and the relevant United States patent records are the controlling sources for listed patent numbers, expiration dates, and any pediatric-exclusivity adjustment.[2][3]

A commercial diligence review should separate three issues:

Question	Commercial significance
Is a patent listed in the Orange Book?	Determines whether an ANDA applicant must address the patent with a certification
Does the patent claim the formulation or only a method of use?	Defines design-around options
Is the patent enforceable and unexpired?	Determines litigation and launch risk

An excipient supplier does not generally infringe a formulation patent merely by selling a conventional excipient. Risk increases when the supplier provides a customized composition, proprietary coating system, or manufacturing process that is covered by a formulation claim and is supplied with knowledge of the intended use.

When does THIOLA EC lose exclusivity?

THIOLA EC exclusivity has several components:

• Patent protection for the delayed-release formulation.
• Any Orange Book-listed method-of-use protection.
• FDA regulatory exclusivity associated with the NDA.
• Potential pediatric exclusivity, if granted and applicable.
• Commercial protection from manufacturing complexity and limited market size.

The original tiopronin product does not provide the same protection as THIOLA EC. A generic applicant may seek approval for tiopronin in a different dosage form or for a different release profile, subject to FDA requirements.

The commercially relevant date is not simply the expiration of a single patent. Generic entry depends on:

• Listed patent expiration
• Paragraph IV litigation
• Thirty-month stay provisions
• FDA approval timing
• Product-specific labeling
• Ability to demonstrate bioequivalence
• Availability of suitable manufacturing technology

What is the Orange Book status of THIOLA EC?

THIOLA EC is an FDA-approved prescription drug listed in the Orange Book under tiopronin delayed-release tablets. Orange Book records identify the approved product, dosage form, strengths, patent listings, and exclusivity information.[2]

The Orange Book does not eliminate technical uncertainty for an ANDA applicant. A generic manufacturer must still demonstrate pharmaceutical equivalence and bioequivalence. For a delayed-release product, that can require control of:

• Acid resistance
• Enteric release
• Particle-size distribution
• Tablet hardness
• Coating composition
• Dissolution variability
• Stability under accelerated conditions

A formulation that uses the same broad excipient categories may still fail to match the reference product’s release behavior.

Are there Paragraph IV challenges to THIOLA EC?

A Paragraph IV certification would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. Public FDA records and litigation databases should be reviewed for each current ANDA, patent number, and complaint date.

The likely challenge points for THIOLA EC are:

• Whether the delayed-release formulation is obvious in view of conventional tiopronin tablets and enteric systems.
• Whether the claims adequately distinguish the claimed formulation from prior art.
• Whether a proposed generic uses a different enteric polymer or coating architecture.
• Whether method-of-use claims are relevant to the proposed label.
• Whether the patent claims are enabled across the full scope.

The most probable generic strategies are a direct ANDA for delayed-release tablets or a formulation designed around the listed coating and tablet-core claims. A 505(b)(2) pathway could be relevant for a materially different pediatric dosage form, but it would not automatically avoid patent litigation.

Which companies are challenging THIOLA EC?

Publicly identifiable challengers should be determined from FDA ANDA records and federal court filings. The relevant parties may include generic manufacturers, contract development and manufacturing organizations, and specialty pharmaceutical companies.

The market has a limited patient population, so a challenger may prefer licensing, acquisition, or a settlement rather than prolonged litigation. A successful generic launch would likely require a specialized formulation program, not a conventional immediate-release tablet.

No biosimilar challenge applies because tiopronin is a small molecule. The relevant competitive threats are generic delayed-release tablets, alternative tiopronin dosage forms, compounded products, and future cystinuria therapies.

How does THIOLA EC compare with generic tiopronin?

Issue	THIOLA EC	Generic or alternative tiopronin
Release profile	Delayed release	May be immediate or delayed release
FDA reference	NDA 209817	ANDA or other approved pathway
Pediatric flexibility	100 mg and 300 mg tablets	Depends on approved product
Excipient differentiation	Coating and tablet architecture	Potential design-around
Bioequivalence burden	Reference standard	Must match applicable performance
Patent exposure	Orange Book-listed patents may apply	Paragraph IV or section viii strategy
Biosimilar risk	None	None
Manufacturing complexity	Coating and release control	Depends on dosage form
Commercial differentiation	Formulation, supply, patient support	Price and substitution

An immediate-release tiopronin product is not automatically a substitute for THIOLA EC. Release location, labeling, dosing instructions, and clinical interchangeability determine the practical competitive relationship.

What licensing deals and commercial partnerships are relevant?

The principal commercial asset is the THIOLA franchise, including the delayed-release product and its market access infrastructure. Excipient companies can pursue several partnership models:

• Exclusive supply of an enteric polymer grade.
• Joint development of a pediatric multiparticulate product.
• Co-development of an odor-masked formulation.
• Manufacturing technology transfer.
• Dual-source qualification for critical excipients.
• License of a coating dispersion or microencapsulation platform.
• Supply agreement tied to an ANDA or 505(b)(2) program.

A supplier with regulatory documentation, multiple manufacturing sites, and demonstrated pharmaceutical-grade consistency is more valuable than a low-cost commodity supplier. Drug-product companies may also seek freedom-to-operate opinions and confidentiality around coating composition and process parameters.

What manufacturing and IP barriers affect generic entry?

The principal barriers are formulation reproducibility and patent claim scope. Generic manufacturers must control:

1. Tablet-core uniformity.
2. Coating thickness and weight gain.
3. Acid-stage integrity.
4. Buffer-stage release.
5. Split-tablet performance.
6. Stability under humidity stress.
7. Sulfur-related odor and impurity control.
8. Commercial-scale coating throughput.

Excipient suppliers can reduce these barriers by providing prequalified systems with defined viscosity, particle size, solids content, plasticizer compatibility, and coating performance.

The most defensible commercial position is a platform that solves a specific product problem, such as pediatric dosing or robust enteric release, while avoiding the exact limitations of the reference product’s patent claims.

What is the revenue exposure to THIOLA EC competition?

Cystinuria is a rare disease, and THIOLA EC revenue is concentrated in a specialty patient population. Commercial exposure depends on:

• Number of diagnosed patients receiving tiopronin.
• Persistence of chronic therapy.
• Average daily dose.
• Mix between 100 mg and 300 mg tablets.
• Insurance reimbursement and patient assistance.
• Generic substitution.
• Timing of patent and exclusivity loss.
• Availability of competing formulations.

A delayed-release generic could reduce net pricing rapidly if multiple manufacturers launch. A differentiated pediatric formulation may preserve pricing even after tablet competition because it addresses administration and dose-flexibility problems not solved by a standard generic.

Key Takeaways

• THIOLA EC is a tiopronin delayed-release tablet, not a new chemical entity.
• The main formulation value lies in enteric protection, tablet splitting, stability, and dose flexibility.
• The strongest excipient opportunities are enteric polymers, low-moisture tablet cores, taste and odor masking, and pediatric multiparticulate systems.
• Generic entry depends on Orange Book patents, Paragraph IV litigation, bioequivalence, and manufacturing reproducibility.
• Biosimilar risk does not apply.
• A direct delayed-release generic is more likely to compete on price, while a pediatric or odor-masked formulation could support a separate 505(b)(2) strategy.
• Excipient suppliers with validated coating systems and regulatory-grade documentation have the best licensing and supply opportunities.

FAQs

Can THIOLA EC tablets be crushed for pediatric administration?

The approved labeling instructs patients not to chew or crush the delayed-release tablets.[1] Crushing can disrupt the enteric barrier and change drug release.

Could hypromellose acetate succinate replace the enteric polymer in THIOLA EC?

It could be evaluated as a formulation alternative, but equivalence would require development and comparative dissolution testing across acid and buffer stages. Polymer substitution does not by itself avoid patent claims.

Is lactose a material concern in THIOLA EC development?

Lactose can affect moisture behavior, compaction, impurity formation, and patient acceptability. A lactose-free formulation could support a differentiated product, but it would require new stability and performance data.

Would an enteric-coated granule be a generic version of THIOLA EC?

Not automatically. A granule product may require a different FDA pathway, a different labeling strategy, and evidence that its release and clinical performance are appropriate for the proposed indication.

Can a co-processed excipient create a patentable THIOLA EC alternative?

Potentially. Patentability would depend on the composition, performance, manufacturing process, and prior art. A routine combination of known excipients is less likely to provide strong protection than a system with a measurable release, stability, or manufacturing advantage.

References

1. Mission Pharmacal Company. (2023). THIOLA EC (tiopronin) delayed-release tablets: Prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/